AZITROMICIN 500
Ask a doctor about a prescription for AZITROMICIN 500
How to use AZITROMICIN 500
INSTRUCTIONS for medical use of the medicinal product Olimel N9E
Olimel N9E
Composition:
active substances: alanine; arginine; aspartic acid; glutamic acid; glycine; histidine; isoleucine; leucine; lysine acetate (equivalent to lysine); methionine; phenylalanine; proline; serine; threonine; tryptophan; tyrosine; valine; sodium acetate trihydrate; potassium chloride; magnesium chloride hexahydrate; sodium glycerophosphate, hydrated; glucose, monohydrate (equivalent to anhydrous glucose); calcium chloride, dihydrate; refined olive oil; refined soybean oil.
Pharmaceutical form
Emulsion for infusion.
Main physical and chemical properties
glucose solution with calcium and amino acid solution with electrolytes: clear, colorless or slightly yellow, practically free from particles;
lipid emulsion: homogeneous milky liquid.
Pharmacotherapeutic group
Solutions for parenteral nutrition. Combinations.
ATC code B05B A10.
Pharmacological properties
Pharmacodynamics
The content of nitrogen (L-amino acid series) and calories (glucose and triglycerides) in the Olimel N9E preparation makes it possible to maintain an adequate nitrogen/calorie ratio.
The preparation also contains electrolytes.
Pharmacokinetics
The ingredients of the Olimel N9E preparation (amino acids, electrolytes, glucose, and fats) are distributed, metabolized, and excreted by the same pathways as the individual components.
Clinical characteristics
Indications
For parenteral nutrition of adults and children over 2 years of age when oral or enteral nutrition is impossible, insufficient, or contraindicated.
Contraindications
Age under 2 years.
Hypersensitivity to egg proteins, soy, peanuts, or corn/corn products (see section "Special warnings and precautions for use"), or to any of the active substances or excipients.
Inborn errors of amino acid metabolism.
Expressed hyperlipidemia or severe lipid metabolism disorders characterized by hypertriglyceridemia.
Severe hyperglycemia.
Pathologically elevated plasma concentrations of sodium, potassium, magnesium, calcium, and/or phosphorus.
Interaction with other medicinal products and other forms of interaction
No interaction studies have been conducted.
Olimel N9E should not be administered simultaneously with blood through the same infusion system due to the possibility of pseudoagglutination.
Special warnings and precautions for use
Too rapid administration
Too rapid administration of any complete parenteral nutrition solution may lead to severe or fatal consequences.
Infusion and monitoring
Infusion should be stopped immediately if any symptoms of an allergic reaction appear (such as sweating, increased body temperature, chills, headache, skin rash, or shortness of breath).
Adverse reactions
Potential undesirable effects may occur as a result of incorrect use (e.g., overdose, too high infusion rate) (see sections "Special warnings and precautions for use" and "Overdose").
Dosage and administration
Dosage
Olimel N9E is contraindicated for use in children under 2 years of age due to the inappropriate composition and volume (see sections "Pharmacodynamics", "Pharmacokinetics", and "Special warnings and precautions for use").
Children over 2 years of age
No studies have been conducted in pediatric patients.
Overdose
In case of incorrect use (overdose and/or exceeding the recommended infusion rate), signs of hypervolemia and acidosis may appear.
Adverse reactions
Potential undesirable effects may occur as a result of incorrect use (e.g., overdose, too high infusion rate) (see sections "Special warnings and precautions for use" and "Overdose").
Shelf life
2 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C. Do not freeze. Store in a place inaccessible to children.
Incompatibility
Do not add other medicinal products or substances to any of the chambers of the bag or to the reconstituted emulsion without first ensuring their compatibility and stability of the resulting solution (in particular, the stability of the fat emulsion).
Release category
Prescription only.
Manufacturer
Baxter S.A. / Baxter SA.
Boulevard Rene Branquart 80, Lessines, 7860, Belgium / Boulevard Rene Branquart 80, Lessines, 7860, Belgium.
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a licensed doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to AZITROMICIN 500Dosage form: tablets, 500 mgActive substance: azithromycinManufacturer: НОБЕЛ ІЛАЧ САНАЇ ВЕ ТІДЖАРЕТ А.Ш.Prescription requiredDosage form: tablets, 500 mgActive substance: azithromycinManufacturer: КРКА, д.д., Ново местоPrescription requiredDosage form: tablets, 250mgActive substance: azithromycinManufacturer: Ауробіндо Фарма Лімітед - Юніт VІІPrescription required
Alternatives to AZITROMICIN 500 in other countries
The best alternatives with the same active ingredient and therapeutic effect.
Alternative to AZITROMICIN 500 in Іспанія
Alternative to AZITROMICIN 500 in Польща
Online doctors for AZITROMICIN 500
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for AZITROMICIN 500 – subject to medical assessment and local rules.
Get updates and exclusive offers
Be the first to know about new services, marketplace updates, and subscriber-only promos.
